Loading stock data…
kr256.55-0.10 (-0.04%)
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Novo Nordisk A/S in the Healthcare sector is trading at $256.55 with a market capitalization of $1.3T. Wall Street consensus targets $306.51 (23 analysts), implying a +19.5% move over the next 12 months. The stock is currently near its 52-week low of $224.25, remaining 10.6% below its 200-day moving average. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
| Metric (DKK) | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
| Total Revenue | kr76.86B↑ | kr74.98B↓ | kr79.14B↓ | kr96.82B↑ | kr78.49B |
| Gross Profit | kr64.01B↑ | kr57.07B↓ | kr64.00B↓ | kr83.22B↑ | kr61.39B |
| Operating Income | kr33.45B↑ | kr23.68B↓ | kr31.74B↓ | kr59.62B↑ | kr27.06B |
| Net Income | kr26.50B↑ | kr20.01B↓ | kr26.89B↓ | kr48.56B↑ | kr20.99B |
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabet...